Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer.
Drizyte-Miller K, Engstrom LD, Klomp JA, Stalnecker CA, Stamey AG, Taylor KE, Roach MK, Robb R, Waters LM, Calinisan A, Degan S, Chang WH, Helu XM, Nguyen D, Baldelli E, Pierobon M, Petricoin EF, Briere DM, Hallin J, Christensen JG, Bryant KL, Cox AD, Olson P, Der CJ.
Drizyte-Miller K, et al. Among authors: robb r.
Cancer Res. 2025 Sep 15;85(18):3540-3557. doi: 10.1158/0008-5472.CAN-25-1507.
Cancer Res. 2025.
PMID: 40694535